SURGICAL ONCOLOGY
Surgical oncology deals especially with the multimodal therapy of gastrointestinal tumors, lung cancer, mediastinal cancers, thyroid cancer and soft tissue tumors.
Our main focus consists of the neoadjuvant radiochemotherapy of
The surgical treatment of these pre-treated tumors is more pretentious than the primary resection and should be performed in “high volume centers” based on the most recent data regarding quality assurance. After neoadjuvant therapy the radical lymphadenectomy is a major component of our surgery. Recently, prospective randomized trials in the Netherlands were able to show a significant survival benefit due to radical lymphadenectomy in patients with esophageal and gastric cancer.
The radio frequency ablation (RFA) of primary liver tumors, especially of hepatocellular cancer, and colorectal liver metastases, has extended the therapeutic spectrum.
The multimodal therapy of solid tumors just works in an interdisciplinary fashion The Center of integrative Oncology has established a tumorboard with a weekly conference (Monday 4.15-5.00 p.m., surgical library). In this conference tumor patients with specific questions are discussed between all participating departments. The final recommendation of this tumorboard regarding the further treatment of each patient is documented and consequently transcribed.
This weekly conference with all experts of cancer therapy provides short-dated each patient with a “second opinion“/recommendation regarding an individual therapeutic concept based on the most recent research reports of each participating departments.
An important research topic of neoadjuvant concepts remains the response prediction of radiotherapy or chemotherapy. Therefore, response prediction is one of our central research topics which is sponsored by external funds (Boll-Stiftung). First results permit to identify patients with esophageal cancer that have a worse response to neoadjuvant radiochemotherapy by using combinations of molecular biomarkers (see research).
Our main focus consists of the neoadjuvant radiochemotherapy of
- esophageal cancer ,
- gastric cancer or cancer of the cardia,
- rectal cancer and
- lung cancer.
The surgical treatment of these pre-treated tumors is more pretentious than the primary resection and should be performed in “high volume centers” based on the most recent data regarding quality assurance. After neoadjuvant therapy the radical lymphadenectomy is a major component of our surgery. Recently, prospective randomized trials in the Netherlands were able to show a significant survival benefit due to radical lymphadenectomy in patients with esophageal and gastric cancer.
The radio frequency ablation (RFA) of primary liver tumors, especially of hepatocellular cancer, and colorectal liver metastases, has extended the therapeutic spectrum.
The multimodal therapy of solid tumors just works in an interdisciplinary fashion The Center of integrative Oncology has established a tumorboard with a weekly conference (Monday 4.15-5.00 p.m., surgical library). In this conference tumor patients with specific questions are discussed between all participating departments. The final recommendation of this tumorboard regarding the further treatment of each patient is documented and consequently transcribed.
This weekly conference with all experts of cancer therapy provides short-dated each patient with a “second opinion“/recommendation regarding an individual therapeutic concept based on the most recent research reports of each participating departments.
An important research topic of neoadjuvant concepts remains the response prediction of radiotherapy or chemotherapy. Therefore, response prediction is one of our central research topics which is sponsored by external funds (Boll-Stiftung). First results permit to identify patients with esophageal cancer that have a worse response to neoadjuvant radiochemotherapy by using combinations of molecular biomarkers (see research).
